tbuckley/cabot-search huggingface dataset:
Intramyocardial lesions in patients dying suddenly and unexpectedly
Authors: H. L. Richardson
Journal: JAMA (1966)

In a 2,000-bed neuropsychiatric hospital, one to two cases of sudden, unexpected death occur per year in patients in whom the postmortem examination reveals no obvious cause of death. Serial electrocardiograms revealed some disorder of electrical activity rhythm and conduction. Between the years 1957 to 1962, small heart sections did not adequately explain abnormal ECGs. Four patients receiving tranquilizers who died suddenly and unexpectedly during 1964 and 1965 were studied. The hearts of 49 nontranquilized patients were compared. Histochemical techniques were used. Lesions were in the intramyocardial arterioles (40μ -80μ ) and the arteriolarcapillary bed (14μ-40μ). Acid mucopolysaccharide was in and about these altered arterioles and degenerating myocardial muscle. The lesions were subendocardial in the right and left atrioventricular conduction bundle and papillary muscles.
The Indiana program for comprehensive medical education
Authors: K. E. Penrod
Journal: JAMA (1969)

Indiana, like many other states, is in need of more health manpower, especially physicians. The cause of the shortage is not, in our case, a failure to provide adequate medical school opportunities. In the last decade the Indiana University School of Medicine has increased its graduating class by 51%, while in the same period the nationwide increase has been only 16%. Furthermore, Indiana is producing 2.5% of the nation's new physician graduates, a figure which matches its proportion of the total population. Yet, in spite of these efforts, shortages are becoming more acute. Recent evidence reveals that barely over half of those who receive their medical education in Indiana establish a practice in the state. "In-migration" of graduates from other states has not matched the "out-migration" of our own graduates. These figures are not, however, unique to our state when compared with those of surrounding states, nor are they unique
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Authors: L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L. D. Bosserman, J. A. Sparano, J. Baselga, P. Mukhopadhyay, V. Valero
Journal: Journal of Clinical Oncology (2011)

1083 Background: Data on chemotherapy for elderly patients (pts) with metastatic breast cancer (MBC) are limited. We performed a retrospective analysis of elderly pts (≥65 years of age) enrolled into the pivotal phase III studies of ixabepilone plus capecitabine versus capecitabine alone in order to determine the efficacy and safety of these agents compared with the overall population. Methods: 1,973 pts with MBC previously treated with or resistant to anthracyclines and taxanes were randomized in two open-label, multinational, phase III studies to receive either ixabepilone (40 mg/m2 IV over 3h q3w) plus capecitabine (1,000 mg/m2 PO BID x 14d q3w) or capecitabine alone (1,250 mg/m2 PO BID x 14d q3w). Due to the similarity of the study populations, individual patient data from both studies were pooled. 251 randomized pts were ≥65 years of age. Results: Efficacy endpoints in the elderly population were consistent with pts <65 years of age. The combination of ixabepilone plus capecitabine was favored over capecitabine monotherapy (Table). Grade 3 or 4 hematologic adverse events (AEs) occurring in >5% of pts receiving ixabepilone plus capecitabine were similar in pts <65 and ≥65 years of age: neutropenia 21% vs 26% and febrile neutropenia 5% vs 10%. Non-hematologic AEs occurring in >5% of pts receiving ixabepilone plus capecitabine were also similar in these age groups and included: fatigue 10% vs 12%, asthenia 6% vs 14%, peripheral sensory neuropathy 14% vs 17%, and hand-foot syndrome 20% vs 19%. Conclusions: The combination of ixabepilone plus capecitabine maintains its efficacy in elderly pts with anthracycline and taxane pretreated MBC. Furthermore, the safety profile of ixabepilone plus capecitabine is similar in pts <65 and ≥65 years of age. <65 years of age ≥65 years of age Ixa + cape cape Ixa + cape cape n 751 740 104 116 ORR,* n (%) 317 (42) 194 (26) 38 (37) 22 (19) Median PFS, mo 5.6 4.2 5.5 3.9 HR (95% CI) 0.81 (0.73–0.90) 0.77 (0.59–1.02) n 868 853 116 135 Median OS, mo 14.7 13.9 13.9 12.2 HR (95% CI) 0.90 (0.81–1.01) 1.07 (0.81–1.40) * ORR and PFS were computed on all randomized pts with measurable disease strata.
MEASLES VACCINE
Authors: Albert Z. Kapikian
Journal: JAMA (1963)

The quest for a vaccine to combat measles has been challenging medical scientists for centuries. The earliest statement of which we have record concerning such a vaccine dates back to 1757 when Alexander Monro, Jr.,<sup>1</sup>professor of anatomy at the University of Edinburgh, commented as follows: "How successful inoculation of smallpox has turned out is known to all, but I regard it as altogether certain that inoculation of measles will be much more useful and successful.... If measles were really to be induced by inoculation artificially produced, it is very likely that the lungs would be more free from inflammation, and in general the disease would attack the skin only. If this should turn out so, what a great profit and utility it would bring to mankind!" Two years later, in 1759, Francis Home,<sup>2</sup>an Edinburgh physician, recorded experiments in which he inoculated volunteers by the cutaneous route
Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure
Authors: N Rolando
Journal: Hepatology (1993)

To compare the efficacy of a selective parenteral and enteral antimicrobial regimen in patients with fulminant liver failure, we classified 104 patients on reaching grade II encephalopathy as infected or noninfected. Patients who were infected were randomly assigned to receive IV cefuroxime (group 1) or selective parenteral and enteral antimicrobial regimen (group 2). Noninfected patients were randomly selected to receive either selective parenteral and enteral antimicrobial regimen (group 3) or no initial antimicrobials until clinically indicated (group 4). The four groups were comparable regarding age, sex, cause of disease, coma grade, international normalization ratio, presence of kidney failure and indicators of poor prognosis on admission to the study. Clinical parameters such as white cell count, temperature or changes in the chest radiograph, which were used to stratify patients into those infected or not, were not good predictors of infection because early infection rates were similar in the two groups. Three patients died within 24 hr and were excluded from the analysis. We found 42 microbiologically confirmed infections: group 1, 6 of 21; group 2, 8 of 21; group 3, 9 of 28; and group 4, 19 of 31. A reduction in infection was seen between groups 3 and 4 (p < 0.05). Patients receiving the selective parenteral and enteral antimicrobial regimen (groups 2 and 3) had fewer infections than the control group (group 4) (p < 0.005). Groups receiving early antimicrobial therapy (groups 1, 2 and 3) had a lower incidence of infection compared with group 4 (p < 0.0005). Overall, 55.5% survived, with no significant difference between the four groups. Of 36 patients who fulfilled criteria for liver transplantation, 15 of 24 patients who received early antimicrobials (groups 1, 2 and 3) and 3 of 12 control patients (group 4) underwent transplantation (p < 0.05). Selective parenteral and enteral antimicrobial regimen reduces the risk of infection in patients with fulminant liver failure, but this effect is probably related to the early administration of antimicrobials. No reduction in length of stay in the unit or in the cost of antimicrobials was found. (HEPATOLOGY 1993;17:196–201.)
Potential Chlorpyrifos Exposure to Residents Following Standard Crack and Crevice Treatment
Authors: Sandra L. Byrne, Bradley A. Shurdut, Donald G. Saunders
Journal: Environmental Health Perspectives (1998)

Multipathway exposures were evaluated for residents of houses over a 10-day period following a crack and crevice application of a chlorpyrifos-based formulation. Three multiroom houses with two adults each were treated. Air concentration, total deposition, and dislodgeable residues on horizontal surfaces were measured to assess potential respiratory, oral, and dermal exposures, respectively, in treated and untreated high activity rooms. In addition, urine samples collected from the adults were analyzed for the primary metabolite of chlorpyrifos, 3,5,6-trichloropyridinol, to determine absorbed dose. The maximum chlorpyrifos air concentration observed was 2.3 microgram/m3, with air concentrations generally decreasing to levels ranging from 0.1 to 0.3 microgram/m3 within 10 days. Carpet dislodgeable residues, used to evaluate the amount of residues potentially transferred upon contact, were less than the analytical method limit of quantitation (1.6 microgram/m2). Hard plastic balls placed in the homes on the day before application contained no detectable dislodgeable residues (<6.5 microgram/m2). Ten-day cumulative nontarget residues deposited on surfaces, as determined by deposition pads, were less than 2.3 microgram/100 cm2. Deposition samples from all living area floors collected 2 hr after application contained less than 9.9 microgram/100 cm2. Therefore, contact with household surfaces and subsequent hand-to-mouth activity are not expected to significantly contribute to overall exposure. Estimated exposures to children, based on the passive dosimetry measurements, ranged from 0.26 to 2.1% of the no observed effect level for plasma cholinesterase depression. In addition, potential exposures to the adult residents, as indicated by the urinary 3,5,6-TCP biomonitoring, did not increase as a result of the application.
EPIDEMIC JAUNDICE
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update in Infectious Diseases
Authors: John G. Bartlett
Journal: Annals of Internal Medicine (1997)

Letters15 July 1997Update in Infectious DiseasesJohn G. Bartlett, MDJohn G. Bartlett, MDJohns Hopkins University School of Medicine; Baltimore, MD 21205Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-2-199707150-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Frankel is correct about the incidence of tuberculosis. The estimate of 1.7 billion refers to the number of patients who are infected with M. tuberculosis, not the number of patients with tuberculosis itself.In Table 2, the footnote for “Incidence” is mislabeled. This refers to the number of patients infected rather than the number of deaths. The number of deaths is given in the next column. With regard to Table 5, trimethoprim-sulfamethoxazole is administered once daily except as otherwise stated. Author, Article, and Disclosure InformationAuthors: John G. Bartlett, MDAffiliations: Johns Hopkins University School of Medicine; Baltimore, MD 21205 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 July 1997Volume 127, Issue 2Page: 165KeywordsInfectious diseasesTuberculosis ePublished: 15 August 2000 Issue Published: 15 July 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
<i>Erratum:</i> Vol. 65, No. 15
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

In the report "Notes from the Field: Respiratory Symptoms and Skin Irritation Among Hospital Workers Using a New Disinfection Product -Pennsylvania, 2015," in the fourth paragraph, the fourth sentence should have read "Full-shift air sample results for hydrogen peroxide ranged from <11 parts per billion (ppb) to 511 ppb; for acetic acid, from <8.8 ppb to 319.4 ppb; and for peroxyacetic acid, from <2.2 ppb to 48 ppb."
Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy
Authors: P. C. Gillette
Journal: JAMA (1985)

Two cases of congestive cardiomyopathy were proved to be due to chronic atrial automatic-focus tachycardia. Surgical elimination of the tachycardia resulted in normalization of cardiac function in both cases. We suggest that patients with congestive cardiomyopathy be carefully screened for supraventricular tachycardia. Patients with chronic supraventricular tachycardia should be treated aggressively to prevent myocardial dysfunction. (<i>JAMA</i>1985;253:391-392)
THE PRESIDENT-ELECT.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Continuing education courses for physicians for the period from Sept 1, 1978, through Aug 31, 1979
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liver Angiosarcoma and Hemangiopericytoma after Occupational Exposure to Vinyl Chloride Monomer
Authors: Izet Hozo, Dinko Miric, Lovre Bojic, Lovel Giunio, Ivo Lusic, Viktor Culic, Miroslav Simunic
Journal: Environmental Health Perspectives (2000)

Various malignant tumors of the liver, especially liver angiosarcoma, have been described after occupational exposure to vinyl chloride monomer. We present the case records and pathologic findings of two plastic industry workers who had been exposed to high concentrations of vinyl chloride. These workers developed hepatic neoplasms, angiosarcoma, or hemangiopericytoma. We discuss the histogenesis of these tumors; the common vascular origin and the mutual transformation of these two tumors suggest that the hemangiopericytoma may also have developed during occupational exposure to high concentrations of vinyl chloride monomer.
Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy
Authors: F. E. Husserl
Journal: JAMA (1979)

Renal papillary necrosis occurred after fenoprofen calcium administration in a patient with systemic lupus erythematosus and urinary tract infection. Possible mechanisms of renal damage may be hypersensitivity, decreased blood flow, and decreased production of a prostaglandin E-like substance. (<i>JAMA</i>242:1896-1898, 1979)
Deutsch's Letters.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
West Nile Virus
Authors: R B Craven, J T Roehrig
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) &amp; carboplatin (CARBO) in pts with 1<sup>st</sup> line non-squamous NSCLC.
Authors: Dusan Kotasek, Brett Gordon Maxwell Hughes, Ben Markman, Michael Millward, Esther Holgado, Michael B. Jameson, Dean Laurence Harris, Robert J. Stagg, Ann M. Kapoun, Jakob Dupont, Mark James McKeage
Journal: Journal of Clinical Oncology (2015)

8045 Background: Delta-like ligand 4 (DLL4) activates the Notch pathway & is important for cancer stem cell (CSC) survival. DEM is a humanized IgG2anti-DLL4 antibody that has been shown to inhibit tumor growth, decrease CSC frequency & cause dysfunctional sprouting of new vessels resulting in an antiangiogenic effect in human tumor xenograft models. Methods: Pts received DEM (2.5 or 5 mg/kg), PEM 500 mg/m2 & CARBO (AUC = 6) every 3 weeks X 6 cycles followed by maintenance DEM (cohorts 1-4) or truncated DEM (5 or 7.5 mg/kg), PEM 500 mg/m2& CARBO (AUC = 6) every 3 weeks X 4 cycles followed by maintenance PEM (cohorts 5 & 6). The objectives were to determine the MTD, safety, efficacy, immunogenicity, pharmacokinetics & biomarkers of Notch signaling. Results: Thirty-nine pts were enrolled; 6 received 2.5 mg/kg, 20 received 5 mg/kg, 6 received 7.5 mg/kg of truncated DEM & 7 received 5 mg/kg of truncated DEM. Related AEs in > 20% of pts were: nausea (51%), fatigue (46%), hypertension (46%), vomiting (31%), edema (26%), neutropenia (26%), increased B-type natriuretic peptide (BNP) (26%) & anemia (21%). Increased BNP values are an early indicator of the cardiac effects of DEM & mildly elevated values are being used to initiate cardioprotective therapy with an ACE inhibitor or carvedilol. Two pts receiving 5 mg/kg developed reversible pulmonary hypertension & heart failure on days 167 & 183, respectively. As a result, DEM treatment was limited to 63 days in cohorts 5 & 6. One of 33 (3%) evaluable pts had a RECIST CR, 15 (45%) had a PR & 13 had SD. The Kaplan Meier estimated median progression free survivals for the 2.5, 5, truncated 5 & truncated 7.5 mg/kg pts were 4.3, 5.3, not yet reached & 4.4 months, respectively. Eight pts who discontinued the study for a reason other than progression (6 continued to receive CARBO &/or PEM off-study) were progression-free through Days 314+, 408+, 448+, 456+, 546+, 677+ 680+ & Day 850. Conclusions: This therapy was generally well tolerated with nausea, fatigue & hypertension being the most common drug related toxicities. Encouraging early clinical activity has been observed. Biomarker data showed modulation of the Notch pathway. Final data will be presented. Clinical trial information: NCT01189968.
Course of Lectures on Venereal Affections Delivered at the Hopital Du Midi, Paris
Authors: P. Ricord
Journal: BMJ (1843)

Extraordinary case of a Jewish child infected by the operation of circumcision-Peculiarities of chancre arising from its seat-Chancres on d&,erentparts of the penis; in the urethra; in the female; in unusual situation-Prognosis of chancre: first, with regard to its local consequences; secondly, with regard to the chance of bubo; thirdly, with regard to the chance of secondary symptoms- Aphorisms on this point-Period at which allfear may cease.